A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Recruiting

Phase 2

Ianalumab with IC TPO-RAA Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Sponsor:

Novartis Pharmaceuticals

Code:

NCT07421167

Conditions

Primary Immune Thrombocytopenia (ITP)

Primary Evans Syndrome (ES)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ianalumab

thrombopoietin receptor agonist (TPO-RA)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-18. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-07-14.